Pioneering Alzheimer’s Blood Test Technology Lands in Lecheng, Ushering in a New Era of Early Screening

Introduction: In a groundbreaking development, AlzOn+, an internationally cutting-edge early blood testing technology for Alzheimer’s disease, has officially been introduced at Ruijin Hainan Hospital (Hainan Boao Lecheng Research Hospital), affiliated with Shanghai Jiao Tong University School of Medicine, within the Lecheng Pilot Zone. The successful completion of the first batch of sample tests marks a significant milestone in China’s Alzheimer’s early screening capabilities, offering new hope to countless families.

Alzheimer’s disease (AD), the most common neurodegenerative disease, exhibits pathological changes that can occur silently 15 to 20 years before clinical symptoms appear. It is characterized by strong concealment, prolonged progression, and irreversibility. One of the core pathological features of AD is the abnormal aggregation of β-amyloid (Aβ) in the brain, forming neurotoxic Aβ oligomers that damage neuronal function and ultimately lead to cognitive decline.

AlzOn+ technology detects the level of neurotoxic β-amyloid (Aβ) oligomerization in plasma, enabling assessment of whether individuals have Aβ pathological changes. It can be used to evaluate pathological states related to subjective cognitive decline (SCD), mild cognitive impairment (MCI), and Alzheimer’s disease (AD). Compared to traditional testing methods, this technology directly detects Aβ oligomerization levels closely associated with neurotoxicity, rather than traditional Aβ monomers or ratios, resulting in more precise detection targets.

For years, AD diagnosis in China has mainly relied on neuropsychological assessment, positron emission computed tomography (PET-CT), or cerebrospinal fluid testing. However, these traditional methods have significant limitations: high costs, substantial patient trauma, complex operational procedures, and often only confirming diagnosis after obvious cognitive impairment has occurred, missing the golden window for early intervention.

As the world’s first AD early blood testing product based on SI-MDS technology (combining sample incubation techniques with the MDS platform), AlzOn+ offers two core advantages. First, the detection targets are more precise, directly measuring Aβ oligomerization levels closely related to neurotoxicity. Second, through sample incubation techniques, the Aβ oligomerization differences between AD patients and healthy individuals are enhanced, resulting in more stable test results and significantly improved detection sensitivity and specificity.

AlzOn+ testing technology is suitable for two populations: asymptomatic individuals aged 40 and above, for early Alzheimer’s disease risk screening to identify potential risks at the disease’s nascent stage; and patients aged 60 and above experiencing cognitive symptoms, as an important aid for auxiliary diagnosis. Through early screening, high-risk populations can identify pathological risks during the asymptomatic period, enabling disease progression delay through lifestyle interventions, management of underlying conditions, and other methods. This truly achieves a closed-loop brain health management system of “early screening, early diagnosis, early intervention.”

To provide convenient access to this cutting-edge testing service for the general public, there are currently two main application channels for this testing technology. The first is to register at the Neurology Department of Ruijin Hainan Hospital, where during the consultation, you should explain any cognitive-related discomfort or testing needs to the neurologist. The doctor will issue a testing application based on your specific situation. After payment, you can go to the designated location for blood sampling. The second option is to directly visit the Physical Examination Center of Ruijin Hainan Hospital. Under the guidance of the center’s staff, you can select the Alzheimer’s disease blood testing special project, and after payment, complete the testing.

Dr. Kang Wenyan, Chief Physician of Neurology at Ruijin Hainan Hospital, advises that early screening for Alzheimer’s disease is crucial for disease prevention and intervention. She recommends that individuals over 40 undergo regular relevant examinations to understand their brain health status in a timely manner.

AlzOn+ has received CE-IVDR certification from the European Union’s In Vitro Diagnostic Medical Device Regulation, as well as approvals from Thailand’s Food and Drug Administration (THFDA), Malaysia’s Medical Device Authority (MDA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), and Indonesia’s Ministry of Health. As of the first half of 2025, the total number of medical institutions providing AlzOn+ testing has reached 965. This extensive international recognition fully demonstrates the technology’s reliability and clinical value.